The site, part of a €637 million investment in the U.K. and Ireland, features sealed unloading docks to ensure zero time out of refrigeration for temp-sensitive products.
While the financial terms of the private transaction were not disclosed, it is believed to be one of the largest such deals in pharmaceutical services in recent years.
Cellular Origins, Cell and Gene Therapy Catapult, and Resolution Therapeutics have been awarded a £1 million grant from the U.K.’s national innovation agency.
The companies plan to combine AbTis’ AbClick linker technology with Lotte’s conjugation manufacturing capabilities at its Syracuse Bio Campus in New York.
The company is working with the CDMO partners in the U.K. and Spain to prepare for potential launch of MYR-101 for Canavan disease, pending regulatory approvals.
The new 194,000-square-foot lab complex will house chemical, microbiological and biological testing facilities to support the growing Tianjin plant’s output.
Italian authorities have appointed a special commissioner to ensure the former Catalent facility near Rome is speedily upgraded, given its significant economic impact.
The CDMO is expanding manufacturing sites in Lexington, Kentucky, and Riverview, Michigan, which are essential to its integrated antibody-drug conjugate offering.
The 25,000-square-meter site at Tuas Biomedical Park is slated to start operations by the end of 2025 and GMP manufacturing in early 2026, according to the company.
The expansion includes new high-containment suites and more than doubles the site’s footprint to meet growing global demand for active pharmaceutical ingredients.
The CDMO’s new cold chain warehouse in Latina, which will be integrated directly into the manufacturing site, will go into operation in the first quarter of 2026.
The site, which is expected to be ready for media fill by the end of 2029, is meant to strengthen the CDMO’s aseptic manufacturing capabilities in early clinical development.
The expansion in Plano includes 5,000 square feet of new laboratory space and doubling its Good Manufacturing Practice production capacity for early clinical trial supply.
The partnership between the biopharma company and CDMO is expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions.
The new site precedes the opening of a Yokohama manufacturing facility slated to be operational in 2027 with services for biologics, cell therapies, and messenger RNA.
The site in Hopewell will now incorporate an additional 26,000 square feet of drug substance manufacturing suites, laboratories, storage, dispensing and warehousing.
The CDMO is entering the advanced therapy manufacturing space with the installation of its third FlexFactory platform from Cytiva to meet demand for genomic medicines.
The collaboration seeks to innovate Treg and TIL therapies for autoimmune and solid tumor diseases, streamline workflows, and enhance manufacturing efficiency.
